Core Viewpoint - Nuvectis Pharma, Inc. (NVCT) shows significant upside potential with a mean price target of $19.25, indicating a 108.8% increase from the current trading price of $9.22 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $4.35, suggesting variability in analyst predictions [2] - The lowest estimate of $15 indicates a 62.7% increase, while the highest estimate suggests a 171.2% surge to $25 [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about NVCT's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, two estimates have increased, leading to a 14.2% rise in the Zacks Consensus Estimate [12] - NVCT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Group 1 - Xenon Pharmaceuticals (XENE) closed at $38.28, with a 30.2% gain over the past four weeks, and a mean price target of $56.71 indicating a 48.2% upside potential [1] - The average of 14 short-term price targets ranges from a low of $42 to a high of $65, with a standard deviation of $6.73, suggesting a variability in estimates [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 0.3% over the past month, indicating positive sentiment among analysts [12] - XENE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does suggest a positive direction for price movement [13]

Tarsus Pharmaceuticals, Inc. (TARS) closed the last trading session at $50.90, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $67.13 indicates a 31.9% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $13.74. While the lowest estimate of $41 indicates a 19.5% decline from the current price level, the most optimist ...